𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Method of determining the cost of hydropower objects and their cost effectiveness

✍ Scribed by V. A. Postoev; Ya. L. Gritsevskii; O. A. Grachev


Publisher
Springer
Year
1993
Tongue
English
Weight
429 KB
Volume
27
Category
Article
ISSN
1570-1468

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Bayesian cost-effectiveness analysis wit
✍ Miguel A. NegrΓ­n; Francisco J. VΓ‘zquez-Polo πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 263 KB πŸ‘ 1 views

Cost-effectiveness analysis (CEA) compares the costs and outcomes of two or more technologies. However, there is no consensus about which measure of effectiveness should be used in each analysis. Clinical researchers have to select an appropriate outcome for their purpose, and this choice can have d

The usefulness of average cost-effective
✍ Eugene M. Laska; Morris Meisner; Carole Siegel πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 2 views

We demonstrate that average cost-effectiveness ratios (CERs) play an important role in the evaluation of the cost-effectiveness of treatments. Criticisms of the usefulness of CERs derive mostly from the context of resource allocation under a constrained budget in which some decisions are based on in

The cost-effectiveness of breast cancer
✍ Paul J. Van Der Maas; Harry J. De Koning; B. Martin Van Ineveld; Gerrit J. Van O πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 French βš– 728 KB

The costs and effects of different invitation schedules of breast cancer screening are compared. The effect estimates are based on trials from the USA, Sweden and the Netherlands. The cost estimates use registration data, file studies and organization charts. The calculations were performed with the

Determining the efficacy and cost-effect
✍ Donna J. Graville; Andrew D. Palmer; Peter E. Andersen; James I. Cohen πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 267 KB

## Abstract ## Objectives/Hypothesis: To investigate 1) whether the Provox ActiValve results in increased device‐life in individuals with below average device‐life, 2) whether it is cost‐effective, and 3) whether it has any impact on voice‐related quality of life. ## Study Design: Prospective st